T 1677/11 ((-)-Omeprazole Na/ASTRAZENECA) of 27.11.2012
- European Case Law Identifier
- ECLI:EP:BA:2012:T167711.20121127
- Date of decision
- 27 November 2012
- Case number
- T 1677/11
- Petition for review of
- -
- Application number
- 00108479.7
- IPC class
- C07D 401/12A61P 1/04A61K 31/44
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- The sodium salt of the (-)-enantiomer of omeprazole
- Applicant name
- AstraZeneca AB
- Opponent name
- Farmaprojects, S.A.
Wittkopp, Alexander
Teva Pharmaceutical Industries Ltd.
Actavis Group hf.
LEK Pharmaceuticals d.d.
Hörnchen, Ulrich, Dr. - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- BDS Art 7European Patent Convention Art 100(b)European Patent Convention Art 100(c)European Patent Convention Art 24(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 87European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal Art 15(3)
- Keywords
- Admissibility of partiality objections (no)
Main request, allowable
Added matter (no)
Sufficiency (yes), starting material retrievable from Chemical Abstracts
Novelty (yes), specific salt
Inventive step (yes), post-published evidence (yes), unexpected advantage - Catchword
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is maintained unamended.
3. The objections under Article 24(3) EPC are rejected as inadmissible.